GlycoMimetics Inc Blog | Talkmarkets | Page 1
No data available
No data available
Latest Posts
1 to 15 of 15 Posts
Week In Review: Four China Biopharmas Announce $100+ Million Deals In First Week Of 2020
Article By: ChinaBio® Today Saturday, January 11, 2020 4:11 PM EDT
Apollomics of Hangzhou announced a $189 million agreement to develop two GlycoMimetics novel E-selectin-based immunotherapies in China for leukemia. Apollomics will be responsible for developing uproleselan and GMI-1687.
In this article: LLY, GLYC, BPMC, ZLAB
Read
Late Slide In Tech Mega-Caps Leaves Averages Mixed For Week
Article By: The Fly Saturday, June 10, 2017 10:38 AM EDT
Stocks appeared in line for a slight weekly advance until Friday afternoon, when a sharp decline in a number of mega-cap tech stock pushed the Nasdaq down nearly 2.5% at its low point.
In this article: DFT, DHI, DLR, FOR, JWN, M, THO, VZ, CLDR, AMRI, GIII, NLNK, AAPL, AMZN, FRAN, GOOG, MSFT, YHOO, DVAX, JUNO, BABA, FB, AMBA, GLYC, KITE, BLUE, MIK, ANTM, PLAY, RDUS, LOXO, DLTH, HDS
Read
Biotech Fades After ASCO Abstract Rally
Article By: Rod Raynovich Friday, May 26, 2017 6:29 PM EDT
Biotechs faded today now that the rush of oncology drug news cooled down. Today was dominated by the “red screen” with profit taking mainly in smaller caps and momentum driven oncology stocks.
In this article: MRK, ALNY, ALXN, BMRN, INCY, CELG, CLVS, VRTX, ZIOP, JUNO, PBYI, EPZM, GLYC, KITE, TSRO
Read
ASCO Abstracts Week: Biotech Trends And Hot Stocks
Article By: Rod Raynovich Monday, May 22, 2017 10:58 PM EDT
Today Amgen was down over 2 % on news that its osteoporosis treatment Evenity is unlikely to win FDA approval this year because of a safety risk. Radius Health was up over 6% to $37.30 as their rival drug Tymlos was approved in April.
In this article: MRK, ALNY, IBB, INCY, REGN, AMGN, CLVS, VRTX, FBT, XBI, PUMA, JUNO, EPZM, GLYC, KITE, BLUE, RDUS
Read
GlycoMimetics Surges 100% On Breakthrough Therapy Designation
Article By: Terry Chrisomalis Sunday, May 21, 2017 11:52 PM EDT
On Thursday, GlycoMimetics surged as high 100% after the company announced that it had received FDA breakthrough therapy designation.
In this article: GLYC
Read
GlycoMimetics - High Potential Clinical-Stage Biotech
Article By: StockMatusow Tuesday, May 16, 2017 9:01 AM EDT
GlycoMimetics is a clinical-stage biotech that we feel has significant potential to be a short, mid, and long term winner. The company has a unique and novel platform in which early data looks very promising.
In this article: GLYC Also: BMY, PFE, JAZZ, CALA
Read
Biotech Rally Fizzles As Global Healthcare Issues Weigh…Update-1
Article By: Rod Raynovich Saturday, June 11, 2016 7:01 PM EDT
The strong biotech rally fizzled early this week as longer term healthcare issues weighed on investors. High expectations from breakthrough products were tempered by the lingering long term concerns of drug pricing and healthcare reform.
In this article: BMY, IBB, QQQ, BIIB, XBI, ABBV, GLYC
Read
The 3 Best Developmental Stage Biotech Stocks Surging Now
Article By: Zacks Investment Research Wednesday, May 25, 2016 10:54 PM EDT
Every week, there are small, under-the-radar companies that see their share prices surge immensely. Not all of these companies are worth being bullish on, but the Zacks Rank helps to find companies that might be worth taking a chance on.
In this article: GLYC, VTAE, DMTX
Read
Healthcare Sector Is Looking A Tad Better: M&A Boosts Biotech…Update
Article By: Rod Raynovich Tuesday, May 24, 2016 10:00 PM EDT
A broad rally today surprised many traders. Technology was a leader up 2% followed by healthcare up 1.49%. US new single family home sales hit an 8 year high a sign of growing prospects for the economy.
In this article: BMY, PFE, SNY, RHHBY, ALNY, ANAC, IBB, INCY, MDVN, QQQ, SGEN, BIIB, GILD, XBI, XLV, ABBV, GLYC, XON
Read
Rayno Small Cap Biopharmaceutical Portfolio 2015 In Rally Mode - XBI Up 2.5%
Article By: Rod Raynovich Tuesday, December 29, 2015 9:44 PM EDT
We recommended three new small caps at the October Bioinvestor Forum: Curis, Geron and Ocera Therapeutics. This forum offers the best window on emerging small companies in the fall, a good time to get a head start on biotech small cap investing.
In this article: ARRY, CRIS, GERN, XBI, IMMY, GLYC, FCSC, RXDX, OCRX
Read
Rayno Small Caps Outperform: New Long Idea - Imprimis Pharmaceuticals
Article By: Rod Raynovich Tuesday, December 1, 2015 7:00 PM EDT
Today we added a new small cap speculative pick, Imprimis Pharmaceutical, an emerging pharmaceutical Company focused on developing and commercializing proprietary compounded, customized drug therapies to physicians and patients in the US.
In this article: ARRY, CRIS, GERN, IMMY, GLYC, FCSC, RXDX
Read
Roller Coaster Market Creates Biotech Buying Opportunity
Article By: Rod Raynovich Thursday, August 13, 2015 1:26 PM EDT
Yesterday was one of the craziest trading days of the year triggered by the Chinese Yuan surprise reset.
In this article: FBIOX, ARRY, GILD, GLYC, FCSC, RXDX, BIIB, IBB
Read
Snap-Back Rally In Biotech-But Lagging Other Sectors
Article By: Rod Raynovich Monday, March 30, 2015 11:15 PM EDT
We are in Day Two of the biotech rally that was sparked last Friday with the rumor supported by a Deutsche Bank analyst that Biomarin (BMRN) was a takeover target.
In this article: BMRN, ABBV, PCYC, XBI, XLV, REGN, AMGN, ALKS, CLVS, CLDX, FCSC, FMI, GLYC, ABAX, PACB, XON
Read
Biotech Stocks Hit By Profit Taking-More Volatility Lies Ahead
Article By: Rod Raynovich Tuesday, December 2, 2014 5:00 AM EDT
Don’t blame the consumer and retail sales for the sell-off. Investors have done very well this year with simple indexing.
In this article: CLDX, SGEN, AMGN, BIIB, GILD, XLV, EPZM, GLYC, AGIO
Read
Laidlaw's Yale Jen: Biotech 101 For Buyers And Sellers
Article By: The Life Sciences Report Friday, August 29, 2014 5:36 AM EDT
Former biotech consultant Yale Jen picked up a few tricks advising companies on their pipelines before he came to Wall Street as a sellside analyst.
In this article: GSK, PFE, ISIS, RPRX, BIIB, MSTX, ADMA, GLYC
Read
1 to 15 of 15 Posts